- Home
- HROW vs PCRX Comparison
HROW vs PCRX Comparison
Compare HROW & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HROW
- PCRX
- Stock Information
- Founded
- HROW 1998
- PCRX 2006
- Country
- HROW United States
- PCRX United States
- Employees
- HROW N/A
- PCRX N/A
- Industry
- HROW Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- HROW Health Care
- PCRX Health Care
- Exchange
- HROW Nasdaq
- PCRX Nasdaq
- Market Cap
- HROW 1.1B
- PCRX 1.2B
- IPO Year
- HROW N/A
- PCRX 2011
- Fundamental
- Price
- HROW $34.93
- PCRX $22.90
- Analyst Decision
- HROW Strong Buy
- PCRX Buy
- Analyst Count
- HROW 7
- PCRX 8
- Target Price
- HROW $61.83
- PCRX $28.38
- AVG Volume (30 Days)
- HROW 368.3K
- PCRX 545.0K
- Earning Date
- HROW 08-06-2025
- PCRX 07-29-2025
- Dividend Yield
- HROW N/A
- PCRX N/A
- EPS Growth
- HROW N/A
- PCRX N/A
- EPS
- HROW N/A
- PCRX N/A
- Revenue
- HROW $212,858,000.00
- PCRX $702,772,000.00
- Revenue This Year
- HROW $44.89
- PCRX $7.54
- Revenue Next Year
- HROW $38.22
- PCRX $10.78
- P/E Ratio
- HROW N/A
- PCRX N/A
- Revenue Growth
- HROW 53.49
- PCRX 3.08
- 52 Week Low
- HROW $20.85
- PCRX $11.16
- 52 Week High
- HROW $59.23
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- HROW 70.24
- PCRX 35.82
- Support Level
- HROW $30.81
- PCRX $22.82
- Resistance Level
- HROW $33.27
- PCRX $23.83
- Average True Range (ATR)
- HROW 1.37
- PCRX 0.74
- MACD
- HROW 0.09
- PCRX -0.02
- Stochastic Oscillator
- HROW 88.78
- PCRX 6.22
About HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.